Aurinia Pharmaceuticals (AUPH) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, sales growth, and improving margins. The stock shows solid financial health and reasonable valuation.
Aurinia Pharmaceuticals (NASDAQ:AUPH) shows strong growth metrics, including surging earnings, revenue, and cash flow, making it a candidate for investors following Louis Navellier’s strategy.
Aurinia Pharmaceuticals (AUPH) shows strong growth, earnings momentum, and improving margins, making it a candidate for investors following Louis Navellier’s strategy.
Aurinia Pharmaceuticals (AUPH) meets Louis Navellier’s growth criteria with strong earnings surprises, accelerating revenue, and improving margins. A solid pick for growth-focused investors.
The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.
Over the past three months, Mainz has seen a staggering 2,500% increase in message volume on Stocktwits, while Aurinia’s engagement has grown just 23%.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To Know:
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation.
